Cancer clinical trials in the region Bretagne

254 currently recruiting clinical trials
Region Bretagne

Phase 3 Multiple myeloma #NCT06152575 #2023-507871-23-00
Symptomatic multiple myeloma Monoclonal component measurable None 1 2 3 or more Monoclonal antibodies Immunomodulator
Systemic Treatment-Naive
13 recruiting sites
Pfizer
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06819007 #2024-516982-35-00
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Serous high grade carcinoma (HGSOC) Endometrioid carcinoma Clear cell carcinoma Mucinous carcinoma Other epithelial ovarian cancer Stage III Stage IV Locally Advanced Metastatic HER2 None Chemotherapy Targeted therapy
BRCA 1/2
10 recruiting sites
Daiichi Sankyo
Phase 3 Amyloidosis #NCT06128629 #2023-507220-23-00
Other Presence Cardiac
5 recruiting sites
Intellia Therapeutics
Phase 3 Amyloidosis #NCT06563895 #2024-513547-82-00
Other Other mutation None Systemic Treatment-Naive Absence
5 recruiting sites
Eidos Therapeutics, a BridgeBio company
Phase 3 Amyloidosis #NCT07052903 #2024-519917-72-00
Other Presence Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3 Thyroid and adrenal gland cancer #NCT04290663 #2024-514603-34-00
Thyroid cancer Differentiated carcinoma Localized None Systemic Treatment-Naive Surgery
Radioactive iodine
28 recruiting sites
Centre François Baclesse
Phase 3 Lung cancer #NCT04613596 #2023-508922-83-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic KRAS G12C PDL1 Positive (>= 50%) None Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3 Head and neck cancer #NCT06496178 #2023-510322-32-00
Oral cavity Oropharynx Hypopharynx Larynx Squamous cell carcinoma Locally Advanced Metastatic 1 Immunotherapy Chemotherapy
16 recruiting sites
Merus